Table 1. Baseline Demographics and Disease Characteristics.
| Characteristic | No. (%) | |
|---|---|---|
| Chemotherapy plus radiotherapy (n=63) | Chemotherapy alone (n=63) | |
| Sex | ||
| Female | 10 (15.9) | 11 (17.5) |
| Male | 53 (84.1) | 52 (82.5) |
| Age, median (IQR), y | 46.0 (37.0-52.0) | 47.0 (39.0-52.0) |
| Karnofsky performance status score | ||
| 90-100 | 58 (92.1) | 57 (90.5) |
| 70-80 | 5 (7.9) | 6 (9.5) |
| Smoking status | ||
| Smokers | 22 (34.9) | 20 (31.7) |
| Nonsmokers | 41 (65.1) | 43 (68.3) |
| Histologic findings | ||
| Nonkeratinizing undifferentiated (type III) | 60 (95.2) | 61 (96.8) |
| Nonkeratinizing differentiated (type II) | 2 (3.2) | 1 (1.6) |
| Keratinizing (type I) | 1 (1.6) | 1 (1.6) |
| T classification | ||
| T1-T2 | 7 (11.1) | 8 (12.7) |
| T3-T4 | 56 (88.9) | 55 (87.3) |
| N classification | ||
| N0-N1 | 14 (22.2) | 11 (17.5) |
| N2-N3 | 49 (77.8) | 52 (82.5) |
| Bone metastases | ||
| No | 19 (30.2) | 16 (25.4) |
| Yes | 44 (69.8) | 47 (74.6) |
| Liver metastases | ||
| No | 45 (71.4) | 44 (69.8) |
| Yes | 18 (28.6) | 19 (30.2) |
| Lung metastases | ||
| No | 45 (71.4) | 46 (73.0) |
| Yes | 18 (28.6) | 17 (27.0) |
| Treatment responsea | ||
| Complete | 3 (4.8) | 4 (6.3) |
| Partial | 60 (90.4) | 59 (93.7) |
| Metastatic lesionsa | ||
| 1-2 | 19 (30.1) | 20 (31.7) |
| ≥3 | 44 (69.8) | 43 (68.3) |
Abbreviation: IQR, interquartile range.
a
Treatment response and number of metastatic lesions were evaluated after 3 cycles of chemotherapy (at randomization), whereas remaining other clinical characteristics were evaluated before chemotherapy.